Trial Profile
Phase II Study to Evaluate the Efficacy of Brentuximab Vedotin in Patients With Steroid-Resistant Acute GVHD
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2013
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Graft-versus-host disease
- Focus Biomarker; Therapeutic Use
- 26 Jun 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Jun 2012 New trial record